{"commentary":{"count":69,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":56,"x_video":8,"youtube":4,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06958328\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"LAP100","nct_id":"NCT06958328","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lap100-nct06958328. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"LAP100","arms":[{"description":"See Detailed Description.","label":"Arm I (Options 1, 2, or 3)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo dose-escalated RT daily, every other day, or twice weekly for 5 fractions or daily for 25 fractions (with or without concurrent fluorouracil or capecitabine for 25 fractions only). The 5-fraction regimen is preferred when feasible. After completing dose-escalated RT, patients who received less than 6 months of chemotherapy at study entry are encouraged to receive the remaining chemotherapy to total 6 months of chemotherapy. Patients may continue chemotherapy treatment beyond 6 months at physician's discretion. Additionally, patients undergo blood sample collection, CT, MRI and tumor tissue biopsy throughout the study. Patients may optionally undergo PET/CT prior to treatment.","label":"Arm II (dose-escalated RT)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-10-21","type":"ESTIMATED"},"conditions":["Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":{"count":356,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biopsy Procedure","type":"PROCEDURE"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Capecitabine","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Dose-escalated Radiation Therapy","type":"RADIATION"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Irinotecan Hydrochloride","type":"DRUG"},{"name":"Irinotecan Sucrosofate","type":"DRUG"},{"name":"Leucovorin Calcium","type":"DRUG"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Nab-paclitaxel","type":"DRUG"},{"name":"Observation Activity","type":"OTHER"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Positron Emission Tomography","type":"PROCEDURE"},{"name":"Questionnaire Administration","type":"OTHER"},{"name":"Radiation Therapy","type":"RADIATION"},{"name":"Tumor Treating Fields Therapy","type":"PROCEDURE"}],"last_update":"2026-08-25","lead_sponsor":"NRG Oncology","official_title":"A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-10-21","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"From randomization to the date of death or last follow-up, assessed up to 3 years"}],"references":[],"start_date":{"date":"2025-08-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT06958328"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lap100-nct06958328"}